^
CANCER:

Solid Tumor

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive
:
A1
NICE - 3 days - (New A2)
BRCA1 mutation
Ovarian Cancer
rucaparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA2 mutation
Ovarian Cancer
rucaparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA1 mutation
Ovarian Cancer
niraparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
BRCA2 mutation
Ovarian Cancer
niraparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
HRD
Ovarian Cancer
niraparib
Sensitive
:
A1
ASCO.org - 3 days - (New A2)
HRD
Ovarian Cancer
rucaparib
Sensitive
:
A2
ASCO.org - 3 days - (New A2)
EGFR T263P + EGFR L858R + MET amplification
Non Small Cell Lung Cancer
erlotinib + capmatinib
Sensitive
:
C4
Front Oncol - 3 days - (New C4)
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A2
PMLive - 4 days - (New A2)
KRAS mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
B
Onco Targets Ther - 5 days - (New C3)
TP53 mutation + KRAS mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
B
Onco Targets Ther - 5 days - (New C3)
RET fusion
Solid Tumor
selpercatinib
Sensitive
:
A1
Eli Lilly Press Release - 5 days - (New A1)
KRAS mutation + KMT2C mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
Onco Targets Ther - 5 days - (New C3)
STRN-ALK fusion
Lung Adenocarcinoma
ensartinib
Sensitive
:
C4
Curr Oncol - 5 days - (New C4)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
toripalimab
Sensitive
:
A1
GlobeNewswire - 6 days - (New A1)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive
:
A1
Cancer Cell Int - 6 days - (New D)
HER-2 positive
HER2 Positive Breast Cancer
MAM-06.301
Sensitive
:
D
Cancer Cell Int - 6 days - (New D)
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Gastric Cancer
nivolumab
Sensitive
:
A1
Int J Cancer - 1 week - (New B)
No biomarker
Melanoma
pembrolizumab
Sensitive
:
A1
Merck (MSD) Press Release - 1 week - (New A1)
No biomarker
Soft Tissue Sarcoma
envafolimab
Sensitive
:
B
Tracon Pharmaceuticals Press Release - 1 week - (New B)
RET fusion
Non Small Cell Lung Cancer
selpercatinib
Sensitive
:
A1
J Clin Oncol - 1 week - (New C3)
FGFR2 rearrangement
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive
:
A1
PRNewswire - 1 week - (New A1)
PD-L1 underexpression
Melanoma
nivolumab / relatlimab
Sensitive
:
A1
Bristol-Myers Squibb Press Release - 1 week - (New A1)
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive
:
A2
Front Oncol - 1 week - (New C4)
MGMT promoter methylation
Glioblastoma
temozolomide
Sensitive
:
A2
Transl Oncol - 1 week - (New D)
HER-2 positive
Colorectal Cancer
trastuzumab + tucatinib
Sensitive
:
B
Seagen Press Release - 1 week - (New B)
ALK translocation
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
C2
Lung Cancer - 1 week - (New C3)
EPHA5 mutation
Non Small Cell Lung Cancer
atezolizumab
Resistant
:
C3
BMC Pulm Med - 1 week - (New C3)
ARID1A mutation
Colorectal Cancer
cetuximab
Resistant
:
C3
Nat Commun - 1 week - (New C3)
ROS1 G2032R
Non Small Cell Lung Cancer
lorlatinib
Resistant
:
C3
Curr Oncol - 1 week - (New C4)
CPEB1 underexpression
Gastric Adenocarcinoma
5-fluorouracil
Sensitive
:
C3
J Gastrointest Oncol - 1 week - (New C3)
CCDC85A-ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive
:
C4
J Cell Mol Med - 1 week - (New C4)
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A1
Lancet Oncol - 2 weeks - (New B)
No biomarker
Prostate Cancer
enzalutamide capsule
Sensitive
:
A1
FDA - 2 weeks - (New A1)
FOLR1 overexpression
Ovarian Cancer
IMGN 853
Sensitive
:
B
IGCS 2022 - 2 weeks - (New C3)
FOLR1 expression
Ovarian Cancer
IMGN 853
Sensitive
:
B
IGCS 2022 - 2 weeks - (New C3)
No biomarker
Triple Negative Breast Cancer
XMT-1660
Sensitive
:
B
Mersana Therapeutics Press Release - 2 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive
:
A1
Breast Cancer Res Treat - 2 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A1
Front Oncol - 2 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
Clin Cancer Res - 2 weeks - (New C3)
ROS1 positive
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
A1
JTO Clin Res Rep - 2 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
savolitinib
Sensitive
:
A1
Front Oncol - 2 weeks - (New C4)
FOLH1 positive
Prostate Cancer
lutetium Lu 177 vipivotide tetraxetan
Sensitive
:
A1
Canada Newswire - 2 weeks - (New A1)
HER-2 underexpression
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
B
Clin Cancer Res - 2 weeks - (New C3)
BRAF mutation
Melanoma
encorafenib + binimetinib
Sensitive
:
C2
Cancer Treat Rev - 2 weeks - (New C3)
BRCA1 mutation
Ovarian Cancer
BAY 1895344
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C4)
EGFR wild-type
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
C3
Nat Med - 2 weeks - (New C3)
DDR
Ovarian Cancer
BAY 1895344
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
MSI-H/dMMR + MLH1 deletion
Endometrial Cancer
dostarlimab
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
FOLR1 positive
Ovarian Cancer
bevacizumab + IMGN 853
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
MSH2 deletion + MSH6 deletion
Endometrial Cancer
dostarlimab
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
MLH1 deletion+ PMS2 deletion
Endometrial Cancer
dostarlimab
Sensitive
:
C3
IGCS 2022 - 2 weeks - (New C3)
ALK rearrangement + PD-L1 overepxression
Non Small Cell Lung Cancer
ALK inhibitor
Resistant
:
C3
Front Immunol - 2 weeks - (New C3)
ALK rearrangement + CTLA4 overexpression
Non Small Cell Lung Cancer
ALK inhibitor
Resistant
:
C3
Front Immunol - 2 weeks - (New C3)
CD27 overexpression
Clear Cell Renal Cell Carcinoma
PD1 inhibitor
Resistant
:
C3
Clin Cancer Res - 2 weeks - (New C3)
SPOP mutation
Prostate Cancer
Androgen receptor inhibitor
Sensitive
:
C3
Clin Cancer Res - 2 weeks - (New C3)
ALK wild-type
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
C3
Nat Med - 2 weeks - (New C3)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression
Lung Adenocarcinoma
pembrolizumab
Sensitive
:
C4
Lung Cancer - 2 weeks - (New C4)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation
Lung Adenocarcinoma
afatinib + pyrotinib
Sensitive
:
C4
Thorac Cancer - 2 weeks - (New C4)
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Resistant
:
D
Nat Commun - 2 weeks - (New D)
CDKN2A overexpression
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Resistant
:
D
Nat Commun - 2 weeks - (New D)
HER-2 overexpression
Ovarian Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
D
IGCS 2022 - 2 weeks - (New D)
ATRX mutation
Uterine Corpus Leiomyosarcoma
BAY 1895344
Sensitive
:
D
IGCS 2022 - 2 weeks - (New D)
No biomarker
Renal Cell Carcinoma
pembrolizumab
Sensitive
:
A1
Lancet Oncol - 3 weeks - (New B)
No biomarker
Biliary Tract Cancer
durvalumab
Sensitive
:
A1
FDA - 3 weeks - (New A1)
PD-L1 overexpression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + abemaciclib
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Triple Negative Breast Cancer
Immunotherapy
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
TP53 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + CP-675206
Resistant
:
B
ESMO 2022 - 3 weeks - (New B)
HLA-A2 positive
Non Small Cell Lung Cancer
OSE 2101
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
EGFR wild-type
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
B
Cancer Med - 3 weeks - (New B)
ALK wild-type
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
B
Cancer Med - 3 weeks - (New B)
KEAP1 mutation
Non Small Cell Lung Cancer
durvalumab + CP-675206
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New B)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
A1
J Cancer Res Clin Oncol - 3 weeks - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New B)
EGFR L858R
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New B)
MET exon 14 mutation
Non Small Cell Lung Cancer
tepotinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
capmatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
A1
J Cancer Res Clin Oncol - 3 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
mobocertinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600E
Colorectal Cancer
cetuximab + encorafenib + binimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Solid Tumor
pembrolizumab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Prostate Cancer
olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
HRD
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
NTRK3 fusion
Solid Tumor
larotrectinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
NTRK2 fusion
Solid Tumor
larotrectinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
encorafenib + binimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
NTRK1 fusion
Solid Tumor
larotrectinib
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive
:
A1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
pembrolizumab
Sensitive
:
A1
J Am Acad Dermatol - 3 weeks - (New C3)
ALK rearrangement
Non Small Cell Lung Cancer
alectinib
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New B)
PD-L1 expression
Bladder Cancer
pembrolizumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Colon Cancer
nivolumab + ipilimumab
Sensitive
:
A2
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
HER2 Positive Breast Cancer
pyrotinib
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Melanoma
pembrolizumab
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pyrotinib
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
HRD
Ovarian Cancer
olaparib
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
HR positive
HER2 Negative Breast Cancer
dalpiciclib
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
DZD9008
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
ER positive
HER2 Negative Breast Cancer
RAD1901
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
RAS wild-type
Colorectal Cancer
cetuximab
Sensitive
:
B
ESMO 2022 - 3 weeks - (New C3)
KRAS mutation
Non Small Cell Lung Cancer
durvalumab + CP-675206
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
PD-L1 expression
Bladder Cancer
durvalumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
BRAF V600E
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Lung Adenocarcinoma
capmatinib
Sensitive
:
C1
Onco Targets Ther - 3 weeks - (New C4)
MSI-H/dMMR
Gastrointestinal Cancer
dostarlimab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation
Solid Tumor
olaparib
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Solid Tumor
olaparib
Sensitive
:
C1
ESMO 2022 - 3 weeks - (New C3)
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
MRTX849
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
FGFR2 amplification
Cholangiocarcinoma
ARQ 087
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Solid Tumor
durvalumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib + durvalumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib + durvalumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
KIT exon 11 mutation
Gastrointestinal Stromal Tumor
imatinib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Cervical Cancer
neratinib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
avelumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 overexpression
Non Small Cell Lung Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 negative
HER2 Negative Breast Cancer
anlotinib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 negative
HER2 Negative Breast Cancer
rivoceranib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
ER mutation
HER2 Negative Breast Cancer
GDC-9545
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
cetuximab + avelumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
EGFR wild-type
Non Small Cell Lung Cancer
anlotinib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
RG6330
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Lung Cancer
trastuzumab + pertuzumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Solid Tumor
RG6330
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MET amplification
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
TP53 wild-type
Solid Tumor
BI 907828
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
MDM2 amplification
Solid Tumor
BI 907828
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
ESR1 mutation
HER2 Negative Breast Cancer
lasofoxifene
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Sensitive
:
C2
ESMO 2022 - 3 weeks - (New C3)
HER-2 expression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Colorectal Cancer
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HRD + BRCA2 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HRD + BRCA1 mutation
Ovarian Cancer
bevacizumab + olaparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
cetuximab + MRTX849
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 exon 20 insertion
Lung Adenocarcinoma
ado-trastuzumab emtansine
Sensitive
:
C3
Anticancer Drugs - 3 weeks - (New C4)
ROS1 rearrangement
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
panitumumab + sotorasib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS mutation
Colorectal Cancer
bevacizumab + PCM-075
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive
:
C3
Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive
:
C3
Cancers (Basel) - 3 weeks - (New C3)
KRAS G12C
Colorectal Cancer
bevacizumab
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
ETV6-NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastric Cancer
KN046 + KN026
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
KN046 + KN026
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF mutation
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 mutation
Non Small Cell Lung Cancer
afatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 overexpression
Non Small Cell Lung Cancer
sintilimab
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
CREBBP mutation
Bladder Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
osimertinib + tepotinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RB1 wild-type
Small Cell Lung Cancer
nivolumab
Sensitive
:
C3
JCO Precis Oncol - 3 weeks - (New C3)
BRAF V600
Pancreatic Cancer
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Glioma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Anaplastic Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Thyroid Gland Papillary Carcinoma
FORE-8394
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 amplification
Lung Cancer
trastuzumab + pertuzumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
KN046
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
KN046
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CEACAM5 overexpression
Gastric Cancer
SAR408701
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRCA2 mutation + HR positive
HER2 Negative Breast Cancer
niraparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRCA1 mutation + HR positive
HER2 Negative Breast Cancer
niraparib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 amplification + KRAS exon 2 wild-type
Colorectal Cancer
trastuzumab + lapatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
BPI-7711
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PIK3CA mutation
Squamous Cell Carcinoma of Head and Neck
PD1 inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
PAK4 overexpression
Melanoma
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
PMS2 mutation
Melanoma
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
TERT mutation
Squamous Cell Carcinoma of Head and Neck
PD1 inhibitor
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KIT mutation
Melanoma
imatinib + toripalimab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CCDC6-RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALPP expression
Endometrial Cancer
anti-ALPP CAR-T cells
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALPP expression
Ovarian Cancer
anti-ALPP CAR-T cells
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HRAS Q61
Bladder Cancer
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
KDM6A mutation
Urothelial Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
TGFB1-L
Ovarian Cancer
CORT125134
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
NR3C1 overexpression
Ovarian Cancer
CORT125134
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + MET overexpression
Non Small Cell Lung Cancer
capmatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + ALK wild-type
Non Small Cell Lung Cancer
capmatinib + PDR001
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + EGFR wild-type
Non Small Cell Lung Cancer
capmatinib + PDR001
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 G778_P780dup
Non Small Cell Lung Cancer
HM 78136B
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12D
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12V
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KEAP1 mutation
Non Small Cell Lung Cancer
pembrolizumab + ramucirumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab + ramucirumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type + BRAF wild-type
Colorectal Cancer
nivolumab + ipilimumab + regorafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KIT mutation
Non Small Cell Lung Cancer
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
CKD-702
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation + PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF V600
Melanoma
vorinostat
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EML4-ALK fusion + ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD3G overexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + ATM wild-type
Non Small Cell Lung Cancer
KRAS inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + SMARCA4 wild-type
Non Small Cell Lung Cancer
KRAS inhibitor
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RET positive + SMARCA4 mutation
Non Small Cell Lung Cancer
RET inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
RET positive + KRAS G12V
Non Small Cell Lung Cancer
RET inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion + TP53 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BONSAI high signature
Renal Cell Carcinoma
cabozantinib tablet
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
NCAM1 overexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MTOR overexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD4 underexpression
Renal Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
SPOP mutation
Prostate Cancer
enzalutamide capsule + abiraterone acetate + apalutamide
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
AR wild-type
Prostate Cancer
abiraterone acetate
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
AR wild-type
Prostate Cancer
enzalutamide capsule
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
GemPred signature
Pancreatic Adenocarcinoma
gemcitabine
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HRD signature
Pancreatic Cancer
FOLFIRINOX
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression + CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CD8 expression
Esophageal Squamous Cell Carcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 negative
Gastroesophageal Junction Adenocarcinoma
nivolumab + regorafenib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + LAG3 overexpression
Gastric Cancer
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ITGAM overexpression + CTLA4 overexpression
Gastric Cancer
nivolumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastric Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR expression + HER-2 expression
Gastric Cancer
ASLAN001
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ER positive + PGR positive
Neuroendocrine Tumor
tamoxifen
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET amplification + MET overexpression
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET overexpression
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CYP4B1 expression
Lung Cancer
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
CLEC3B overexpression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 18 mutation + EGFR exon 21 mutation
Non Small Cell Lung Cancer
afatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-1 expression
Gastroesophageal Junction Adenocarcinoma
nivolumab + ipilimumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
IDH wild-type
Glioblastoma
bevacizumab + retifanlimab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
Chr amplification(15)(q22.31)
Squamous Cell Carcinoma of Head and Neck
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression
Lung Non-Squamous Non-Small Cell Cancer
MEDI5752
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HLA-A*02:01
Uveal Melanoma
ipilimumab + tebentafusp
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
SLFN11 expression
Esophageal Squamous Cell Carcinoma
cisplatin + 5-fluorouracil
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CDK4 amplification
Mucosal Melanoma
dalpiciclib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RAS wild-type
Colorectal Cancer
trastuzumab + tucatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HR positive
HER2 Positive Breast Cancer
trastuzumab + abemaciclib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 negative
Cervical Cancer
pembrolizumab + tirvalimogene teraplasmid
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Adenocarcinoma
crizotinib
Resistant
:
C4
Exp Ther Med - 3 weeks - (New C4)
PTEN mutation
Breast Cancer
TAS-117
Sensitive
:
C4
ESMO 2022 - 3 weeks - (New C4)
IDH1 R132C + PIK3CA E545K + IDH2 R172K
Cholangiocarcinoma
ivosidenib
Resistant
:
C4
NPJ Precis Oncol - 3 weeks - (New C4)
FGFR2 M540_I541insMM
Cholangiocarcinoma
pemigatinib
Sensitive
:
C4
Target Oncol - 3 weeks - (New C4)
FGFR3-TACC3 fusion + FGFR3 V555M
Urothelial Cancer
TYRA-300
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
KIT exon 13 mutation
Gastrointestinal Stromal Tumor
M4205
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
lazertinib + ABN401
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
Non Small Cell Lung Cancer
JIN-A02
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR L858R
Non Small Cell Lung Cancer
JIN-A02
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression
Non Small Cell Lung Cancer
osimertinib
Resistant
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression
Non Small Cell Lung Cancer
erlotinib
Resistant
:
D
ESMO 2022 - 3 weeks - (New D)
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive
:
A1
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive
:
A1
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive
:
A1
KIT positive
Gastrointestinal Stromal Tumor
imatinib
Sensitive
:
A1
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
A1
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive
:
A1
PDGFRA D842V
Gastrointestinal Stromal Tumor
avapritinib
Sensitive
:
A1
No biomarker
Esophageal Cancer
nivolumab
Sensitive
:
A1
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive
:
A1
No biomarker
Ovarian Cancer
niraparib
Sensitive
:
A1
No biomarker
Peritoneal Cancer
niraparib
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A1
ROS1 fusion
Non Small Cell Lung Cancer
entrectinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
dacomitinib
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
lazertinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
cemiplimab
Sensitive
:
A1
No biomarker
Squamous Cell Carcinoma of Head and Neck
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive
:
A1